Status:
COMPLETED
Effect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a RCT
Lead Sponsor:
Pusan National University Yangsan Hospital
Conditions:
Muscular Sarcoidosis
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the SCE on muscle strength, muscle mass, and muscle function in healthy adults for 12 weeks...
Detailed Description
Previous studies have indicated that Schisandra chinensis extract (SCE) may have the ability to prevent skeletal muscle atrophy. Therefore, the investigators conduct a randomized, double-blind, placeb...
Eligibility Criteria
Inclusion
- \<110% of the standard lean body mass as measured using the body composition analyzer InBody 720)
- Body-mass index (BMI) ranging from 18.5 to 30.0 kg/m2
Exclusion
- Abnormal liver or renal function (i.e., serum aminotransferase activity \> 60 IU/L and serum creatinine concentrations \> 1.2 mg/dL)
- Diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dL)
- History of fracture during the previous year
- Uncontrolled hypertension
- History of serious cardiac disease such as angina or myocardial infarction
- History of gastrectomy
- History of medication for psychiatric disease
- Administration of oriental medicine including herbs within the past 4 weeks
- Evidence of relatively high skeletal mass (more than 110% of the standard lean body mass as measured using the body composition analyzer InBody 720)
Key Trial Info
Start Date :
June 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT03402308
Start Date
June 1 2017
End Date
March 1 2018
Last Update
April 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pusan National University Yangsan Hospital
Pusan, Ami-dong, South Korea, 602-739